Expanded Access for Bromodomain and Extra-Terminal (BET) Inhibitor


Study First Submitted Date 2021-11-16
Study First Posted Date 2022-03-31
Last Update Posted Date 2022-10-14
Verification Month Year October 2022
Verification Date 2022-10-31
Last Update Posted Date 2022-10-14

Id Information

Sequence: 40034360
Id Source org_study_id
Id Value CA011-011


Sequence: 42430464 Sequence: 42430465 Sequence: 42430466 Sequence: 42430467 Sequence: 42430468 Sequence: 42430469 Sequence: 42430470
Name Australia Name France Name Italy Name New Zealand Name Sweden Name Switzerland Name United States
Removed True Removed True Removed True Removed True Removed True Removed True Removed True


Sequence: 52324805
Intervention Type Drug
Name BET Inhibitor
Description Bromodomain and Extra-Terminal Inhibitor


Sequence: 48171037
Agency Class INDUSTRY
Lead Or Collaborator lead
Name Bristol-Myers Squibb

Overall Officials

Sequence: 29194059
Role Study Director
Name Bristol-Myers Squibb
Affiliation Bristol-Myers Squibb


Sequence: 30672277
Minimum Age N/A
Maximum Age N/A
Adult True
Child True
Older Adult True

Calculated Values

Sequence: 254302832
Registered In Calendar Year 2021
Were Results Reported False
Has Single Facility False


Sequence: 4373836 Sequence: 4373837 Sequence: 4373838 Sequence: 4373839
Url https://www.bms.com/healthcare-providers/early-patient-access-to-investigational-medicine/investigational-drugs-available.html Url https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html Url https://www.bmsstudyconnect.com/s/US/English/USenHome Url https://www.fda.gov/Safety/MedWatch/SafetyInformation/default.htm
Description Pre-Approval Access (PAA) Healthcare Practitioner Requests Description BMS Clinical Trial Information Description BMS Clinical Trial Patient Recruiting Description FDA Safety Alerts and Recalls

Responsible Parties

Sequence: 28785564
Responsible Party Type Sponsor